“By the end of the year, much of our diagnostic businesses, whether that's equipment or reagents will be localized.”

In context

“ut. So maybe could you just remind us how much of your production and sales in China are manufactured locally and maybe both reagents and on the instrumentation side. Where do you have defensiveness? And where do you need to expand manufacturing if this was to spread broadly to other government agencies, including academics? Rainer Blair: So Puneet, that 20% that you heard about benefit for local manufacturers is actually not the newest of news. It's been out there informally, which is often how it works in China for some time. In fact, I was just in China for a couple of weeks here, taking a close look at what's happening and of course, talking to customers and government officials and, of course, our teams. And we think that we're very well positioned here as it relates to localization. By the end of the year, much of our diagnostic businesses, whether that's equipment or reagents will be localized. And that degree of localization plays well across the portfolio. So while we don't talk about percentages of localization, we think that we're very well positioned here and view this actually as advantageous as opposed to a short-term headwind. Operator: And with that, we'll turn the call back to John Bedford for any additional or closing remarks. John Bedford: Thank you, David, and thank you, everybody. We'll be around all day and the rest of the week for follow-ups. Have a good rest of your Tuesday here. Operator: This does conclude today's program. Thank you for your participation, and you may now disconnect.”